参松养心胶囊及曲美他嗪联用对慢性心力衰竭合并窦性心动过缓患者心功能和HRV相关指标的影响

目的:研究参松养心胶囊与曲美他嗪联用对慢性心力衰竭合并窦性心动过缓患者心功能和HRV相关指标的影响。方法:选取2015年7月至2016年8月石景山医院收治的慢性心力衰竭合并窦性心动过缓患者94例。按照就诊顺序分为观察组与对照组,每组47例。对照组患者予以曲美他嗪治疗,观察组则在对照组的基础上加用参松养心胶囊治疗。分别比较2组临床疗效,治疗前后心功能、24 h动态心电图平均心率以及HRV相关指标变化情况。结果:观察组患者治疗总有效率为97.87%(46/47),显著高于对照组的85.11%(40/47)(P0.05)。治疗前2组患者各项心功能水平比较,差异无统计学意义,分别治疗后观察组患者LVEF、CO、SV、6 min步行距离分别为(53.6±4.1)%、(5.0±0.7)L/min、(46.1±6.9)mL/次、(394.2±60.4)m,均显著高于对照组的(49.2±3.9)%、(4.2±0.6)L/min、(41.4±5.7)mL/次、(363.6±58.2)m(均P0.05)。治疗后观察组与对照组患者24 h动态心电图平均心率分别为(66.8±6.1)次/min、(55.2±6.7)次/min,均显著高于治疗前,而观察组又显著高于对照组(均P0.05)。治疗后观察组患者SDANN、SDNN、r MSSD、PNN50水平分别为(112.6±20.1)ms、(129.2±21.5)ms、(25.2±5.7)ms、(6.0±0.8)%,均显著高于对照组的(85.7±19.2)ms、(94.1±14.5)ms、(20.1±5.8)ms、(2.8±0.7)%(均P0.05)。结论:参松养心胶囊与曲美他嗪联合治疗慢性心力衰竭合并窦性心动过缓的疗效显著,可有效改善患者心功能以及HRV相关指标,有利于促进患者早日康复。

Effects of Shensong Yangxin Capsule Combined with Trimetazidine on Cardiac Function and Related Parameters of HRV in Patients with Chronic Heart Failure with Sinus Bradycardia

To study the effects of Shensong Yangxin Capsule combined with trimetazidine on cardiac function and related parameters of HRV in patients with chronic heart failure with sinus bradycardia.Methods:A total of 94 patients with chronic heart failure with sinus bradycardia in our hospital from July 2015 to August 2016 were selected.According to the visiting order,they were divided into observation group and control group (n=47).Control group patients were given trimetazidine for treatment,and the observation group on the basis of the control group was treated with Shensong Yangxin Capsule respectively.The clinical curative effect,heart function before and after the treatment,24 h dynamic electrocardiogram (ecg) average heart rate and related parameters of HRV changes of two groups were compared.Results:The total effective rate of observation group patients was 97.87% (46/47),which was significantly higher than that of control group 85.11% (40/47) (P<0.05).There was no significant difference in various cardiac function levels of two groups.After treatment,LVEF,CO and SV,6 min walking distance of observation group were (53.6±4.1) %,(5.0±0.7) L/min,(46.1±6.9) mL,(394.2±60.4) m/time respectively,which were significantly higher than that of control group (49.2±3.9) %,(4.2±0.6) L/min,(41.4±5.7) mL,(363.6±58.2) m/time (all P<0.05).24 h dynamic electrocardiogram average heart rate of the observation group and the control group after treatment were (66.8±6.1) times/min,(55.2±6.7) times/min respectively,which were significantly higher than before the treatment,and the observation group was significantly higher than the control group (P<0.05).SDANN,SDNN,rMSSD,PNN50 level of observation group after treatment were (112.6±20.1) ms,(129.2±21.5) ms,(25.2±5.7) ms,(6.0±0.8) %,ms respectively,which were significantly higher than that of control group (85.7±19.2) ms and (94.1±14.5) ms,(20.1±5.8) ms,(2.8±0.7) % (all P<0.05).Conclusion:The curative effect of Shensong Yangxin Capsule combined with trimetazidine in the treatment of chronic heart failure with sinus bradycardia is significantly,which can effectively improve cardiac function in patients as well as the related parameters of HRV,and promote patients recover at an early date.